Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
Mainz Biomed (NASDAQ:MYNZ) has announced a collaborative agreement with Thermo Fisher Scientific to jointly develop and potentially commercialize Mainz's Next Generation colorectal cancer screening product. The collaboration will utilize Thermo Fisher's technologies, instrumentation, and information translation systems to develop proprietary mRNA-based screening tests.
The partnership aims to enhance Mainz Biomed's non-invasive test that targets both early detection of colorectal cancer and precancerous lesions, particularly advanced adenomas. The development will take place at Mainz Biomed's laboratories in Mainz, Germany, focusing on creating a home collection colorectal screening tool with enhanced adenoma detection capabilities.
Mainz Biomed (NASDAQ:MYNZ) ha annunciato un accordo di collaborazione con Thermo Fisher Scientific per sviluppare congiuntamente e potenzialmente commercializzare il prodotto di screening per il cancro del colon-retto di nuova generazione di Mainz. La collaborazione utilizzerà le tecnologie, gli strumenti e i sistemi di traduzione delle informazioni di Thermo Fisher per sviluppare test di screening proprietari basati su mRNA.
Il partenariato mira a migliorare il test non invasivo di Mainz Biomed che si concentra sulla rilevazione precoce del cancro del colon-retto e delle lesioni precancerose, in particolare gli adenomi avanzati. Lo sviluppo avverrà nei laboratori di Mainz Biomed a Mainz, in Germania, concentrandosi sulla creazione di uno strumento di screening per il colon-retto che consenta la raccolta domiciliare e migliori capacità di rilevamento degli adenomi.
Mainz Biomed (NASDAQ:MYNZ) ha anunciado un acuerdo de colaboración con Thermo Fisher Scientific para desarrollar y potencialmente comercializar conjuntamente el producto de detección de cáncer colorrectal de nueva generación de Mainz. La colaboración utilizará las tecnologías, la instrumentación y los sistemas de traducción de información de Thermo Fisher para desarrollar pruebas de detección basadas en ARN mensajero (mRNA).
La asociación tiene como objetivo mejorar la prueba no invasiva de Mainz Biomed que se centra en la detección temprana del cáncer colorrectal y de las lesiones precoces, en particular los adenomas avanzados. El desarrollo tendrá lugar en los laboratorios de Mainz Biomed en Mainz, Alemania, con un enfoque en crear una herramienta de detección de cáncer colorrectal para la recolección en el hogar con mejores capacidades de detección de adenomas.
마인츠 바이오메드 (NASDAQ:MYNZ)는 Thermo Fisher Scientific와 협력 계약을 체결하여 마인츠의 차세대 대장암 검진 제품을 공동 개발하고 잠재적으로 상용화할 것이라고 발표했습니다. 이 협력은 Thermo Fisher의 기술, 기기 및 정보 번역 시스템을 사용하여 mRNA 기반의 독점적인 검진 테스트를 개발하는 데 활용됩니다.
이번 파트너십의 목표는 대장암 조기 발견과 특히 고급 선종을 타겟으로 하는 마인츠 바이오메드의 비침습적 검사를 개선하는 것입니다. 개발은 독일 마인츠에 있는 마인츠 바이오메드의 연구소에서 진행되며, 향상된 선종 탐지 기능을 갖춘 자택 수집 대장 검진 도구의 제작에 집중할 것입니다.
Mainz Biomed (NASDAQ:MYNZ) a annoncé un accord de collaboration avec Thermo Fisher Scientific pour développer conjointement et potentiellement commercialiser le produit de dépistage du cancer colorectal de nouvelle génération de Mainz. La collaboration utilisera les technologies, l'instrumentation et les systèmes de traduction d'informations de Thermo Fisher pour développer des tests de dépistage propriétaires à base d'ARNm.
Ce partenariat vise à améliorer le test non invasif de Mainz Biomed, qui cible à la fois la détection précoce du cancer colorectal et les lésions précancéreuses, en particulier les adénomes avancés. Le développement aura lieu dans les laboratoires de Mainz Biomed à Mainz, en Allemagne, avec un accent sur la création d'un outil de dépistage colorectal à domicile avec des capacités de détection d'adénomes améliorées.
Mainz Biomed (NASDAQ:MYNZ) hat eine Kooperationsvereinbarung mit Thermo Fisher Scientific bekannt gegeben, um gemeinsam das nächste Generation Produkt zur Darmkrebsvorsorge von Mainz zu entwickeln und potenziell zu vermarkten. Die Zusammenarbeit wird die Technologien, Instrumente und Informationsübersetzungssysteme von Thermo Fisher nutzen, um proprietäre mRNA-basierte Screening-Tests zu entwickeln.
Das Ziel der Partnerschaft ist es, den nicht-invasiven Test von Mainz Biomed zu verbessern, der sowohl auf die frühzeitige Erkennung von Darmkrebs als auch auf präkanzeröse Läsionen, insbesondere fortgeschrittene Adenome, abzielt. Die Entwicklung wird in den Laboren von Mainz Biomed in Mainz, Deutschland, stattfinden und sich auf die Schaffung eines Heim-Screening-Tools für den Darm mit verbesserten Adenom-Erkennungsfähigkeiten konzentrieren.
- Strategic partnership with major industry player Thermo Fisher Scientific
- Access to Thermo Fisher's advanced technologies and systems
- Potential for global commercialization of next-generation screening product
- Development of home collection screening capability
- None.
Insights
The collaboration between Mainz Biomed and industry giant Thermo Fisher Scientific represents a significant strategic advancement in the colorectal cancer screening market. This partnership combines Mainz's innovative mRNA-based screening technology with Thermo Fisher's extensive resources and global distribution capabilities.
The deal's value lies in three key aspects:
- Access to Thermo Fisher's advanced technologies and infrastructure will accelerate product development
- Potential commercialization partnership with a
$200+ billion market cap industry leader significantly enhances market reach - Validation of Mainz's technology by a major industry player could attract additional partnerships and investment
For a small-cap company (
The global colorectal cancer screening market presents a substantial opportunity, projected to reach
- Enhanced product development capabilities leveraging Thermo Fisher's expertise
- Potential access to established distribution channels
- Improved market credibility for future partnerships and expansion
The home collection aspect of their screening tool aligns with growing consumer preferences for convenient diagnostic solutions. Combined with superior adenoma detection capabilities, this could drive significant market adoption once commercialized.
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services.
The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed’s Next Generation colorectal cancer screening product. The collaboration will harness Thermo Fisher’s powerful technologies, instrumentation and information translation systems to enable Mainz Biomed to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are redefining standards in early cancer detection. Mainz Biomed’s flagship non-invasive test not only targets the early detection of colorectal cancer but also focuses on precancerous lesions, particularly advanced adenomas, demonstrating significant clinical success in both US and European trials.
The collaboration will leverage combined capabilities to deliver testing solutions being developed at Mainz Biomed’s laboratories in Mainz, Germany.
Guido Baechler, CEO of Mainz Biomed, said: “This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas. Our product development will be greatly enhanced by Thermo Fisher’s knowledge and scalable, class-leading technologies, providing both partners with a means to accelerate the availability of an innovative new test for colorectal cancer screening around the world.”
Peter Jacobs, Director, EMEA Clinical Business Development, Thermo Fisher Scientific, said: “We are excited at the prospect of working with Mainz Biomed on their next generation screening test and are confident that together we will be able to achieve rapid progress and deliver innovative new assays for the global clinical marketplace.”
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What is the purpose of Mainz Biomed's collaboration with Thermo Fisher Scientific?
What technology will MYNZ's new colorectal cancer screening test use?
Where will MYNZ develop its new colorectal cancer screening product?
What are the key features of MYNZ's colorectal cancer screening test?
